Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242139 | 0.80 | KAT2B (0.40) | KAT2BMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL7034304 | 0.80 | PTGER4 (0.43) | KAT2BMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL30148167 | 0.78 | CCR1 (0.38) | SMN1; SMN2ALDH1A1CCR1HTTHSD17B10 | |
| SCHEMBL4005235 | 0.78 | CCR1 (0.38) | SMN1; SMN2ALDH1A1CCR1HTTHSD17B10 | |
| SCHEMBL2552457 | 0.77 | ALDH1A1 (0.50) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1742856 | 0.76 | MAPT (0.39) | KAT2BMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1742858 | 0.76 | MAPT (0.39) | KAT2BMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL2572082 | 0.73 | HTT (0.50) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4737704 | 0.73 | PTGER4 (0.60) | EGFRIGF1R | |
| SCHEMBL7720742 | 0.73 | PKM (0.44) | MAPTSMN1; SMN2ALDH1A1PKMCCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2069324-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | Curis, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008115719-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115719-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | KAT2B 2914/4885MAPT 215/4885SMN1; SMN2 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.